In order to restore splicing and production of matureRNA and functional CFTR protein, the use of antisenseoligonucleotides (ASOs) is being considered (Egan, 2021).More than 40 clinical trials have been conducted to studythe therapeutic potential of ASOs in the treatment of CF. This evidence concerns the gene CFTR and cystic fibrosis.